Bloom Burton, Innovacorp backed Appili to go public on TSX Venture

Appili Therapeutics Inc. has filed a preliminary prospectus for “initial public offering (IPO)” by way of qualifying and distribution of shares issuable for no additional consideration upon the exercise or deemed exercise of 843,956 special warrants at $4.25 issued in multiple tranches in 2018 and 2019.

Mackie Research Capital Corporation, Echelon Wealth Partners Inc. and Bloom Burton Securities Inc. acted as agents for the brokered portion of the special warrant financing.

Halifax, Nova Scotia based Appili Therapeutics is a pharmaceutical company focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease. Since incorporation in 2015, the Company has been focused on building and advancing a diverse portfolio of anti-infective programs.

Bloom Burton Development Corporation, an affiliate of Bloom Burton Securities Inc., and Innovacorp are two largest shareholders of Appili, collectively controlling 58.9% of outstanding shares or 47.3% on a fully diluted basis.

photo credit: Google

Ted Liu

Ted Liu, M.Sc. (Mining, Queen's), MBA (Finance, Toronto), is the Editor of Private Capital Journal, CanadaMetals.ca, TechWire.ca, and the former Editor of Canadian Private Equity. Ted has been passionately tracking Canadian private capital industry since 1992, having most recently served as Research Director for The Canadian Venture Capital and Private Equity Association (CVCA).

Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.